Session: 635. Myeloproliferative Syndromes: Basic Science: Poster III
Hematology Disease Topics & Pathways:
Diseases, Adult, Therapies, Biological Processes, MPN, Technology and Procedures, Study Population, Myeloid Malignancies, flow cytometry, signal transduction
In this study, by a phospho-specific flow cytometry assay, we measured basal and cytokine induced signaling activity of STAT3, STAT5, and ERK1, 2 in the PB CD34+ cells and granulocytes of 53 patients with PMF not receiving therapy: 31 were JAK2V617F mutated (20 heterozygous), 19 CALR+, and 3 MPL+. Thirteen healthy subjects were assessed as controls (CTRLs). STAT3, STAT5, and ERK1, 2 phosphorylation was measured before/following incubation of PB with recombinant IL-6 (Miltenyi Biotec), thrombopoietin (TPO-Peprotech), or phorbol-12 myristate 13- acetate (PMA-Sigma Aldrich) for 15 minutes a 37°C. Red cells were lysed by Lyse/Fix buffer (Becton Dickinson); PB cells were washed and permeabilized by Perm buffer III (BD). The anti human CD34-FITC (BD) was added to all the conditions. Antibodies used for phosphoprotein detection (p-STAT3, p-STAT5, p-ERK1,2) were Alexa Fluor647-conjugated (BD). Isotype controls were used at the same concentrations as test antibodies.
More than 1x106 cells/sample were acquired by a Navios flow cytometer (Beckman Coulter), and analysed by Kaluza software. Both PB CD34+ cells and granulocytes were electronically gated (granulocytes on the basis of physical parameters). Data, calculated as median fluorescence intensity (MFI) test antibody/ MFI isotype control, are shown as (median, range).
We show higher values (p=0.002) of basal p-STAT5 in the PB CD34+ cells of patients (MFI 2.0, 0.99-4.7) than in CTRLs (MFI 1.6, 0.95-2.7), while the STAT3 and ERK1,2 basal phosphorylations are comparable in patients and CTRLs (not shown). Correlations are present between basal p-STAT5 and hemoglobin levels (R= - 0.28, p=0.038), the absolute number of circulating CD34+ cells (R= 0.39, p=0.005), and the percentage of CD34+CXCR4+ cells (R= -0.47, p=0.0007). In addition, basal p-STAT5 of CD34+ cells is significantly correlated (R=0.29, p=0.031) with a severity score including leukocytosis, thrombocytosis, and splenomegaly (myeloproliferation index) and anemia, leukopenia, and thrombocytopenia (myelodepletion index). Basal p-STAT5 is not correlated with mutant JAK2 allele burden. STAT3, STAT5, and ERK1, 2 phosphorylation of granulocytes is comparable in patients and CTRLs (not shown).
TPO induced p-STAT5 (MFI 9.0, 1.0-29) and IL6 induced p-STAT3 values (MFI 7.0, 0.3-14) in CD34+ cells, are higher (p=0.00004 and p=0.0004, respectively) in patients than in CTRLs and are inversely correlated with the percentage of circulating CD34+CXCR4+ cells (R= -0.30, p=0.04 and R= -0.34, p=0.017, respectively). In addition, the induced p-STAT3 values correlate with the severity score (R=0.30, p=0.03) and the absolute number of circulating CD34+ cells (R= 0.34, p=0.014). No correlation is present with mutant JAK2 allele burden. The cytokine induced p-STAT3, p-STAT5, and p-ERK1,2 is comparable in granulocytes from patients and CTRLs.
In conclusion, increased basal STAT5 and induced STAT5/STAT3 phosphorylation characterize circulating CD34+ HPCs, but not granulocytes in patients with PMF. The altered basal STAT5 and induced STAT5/STAT3 phosphorylation is not associated with mutated JAK2 allele burden, but it may affect the disease severity and course. Interestingly, basal STAT5 and induced STAT5/STAT3 phosphorylation appears to modulate CXCR4 expression on CD34+ HPCs. Taken together, our data indicate that the degree of STAT3 and STAT5 activation pathway in PB CD34+ cells of patients with PMF can determine some clinical and biological features of the disease.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts